Celesio AG / Joint Venture 21.06.2010 08:33 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Celesio and Medco Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs Celesio and Medco, two of the world's leading pharmacy-driven healthcare companies, today announced a joint venture with a long-term goal of improving the quality of patients' healthcare through integrated solutions and relieving the financial burden on healthcare payors across Europe. Headquartered in Amsterdam, the 50/50 joint venture, Medco Celesio B.V., combines Medco and Celesio's strengths in pharmacy-driven clinical care. Medco Celesio B.V. is designed to help patients with chronic or complex conditions, such as diabetes, asthma, high-cholesterol and heart disease. It will concentrate on innovative, integrated clinical services designed to improve patient adherence - meaning following doctors orders - integrate care across multiple providers, and enhance safety and efficiency across the healthcare system. The joint venture will go into operation initially in Germany in 2010, including the collaboration of the parent companies' respective mail order pharmacies, DocMorris and Europa Apotheek Venlo. It will then extend rapidly in phases to the major European markets, including the U.K., France, Spain and Italy. Over time, it is planned to expand its geographic footprint into as many as 27 EU member states plus Switzerland and Norway. The joint venture will cooperate closely with health policymakers, funding bodies, pharmacies, healthcare providers and their umbrella organizations, producers of pharmaceuticals, patients' associations and leading research institutes. Contacts: Investor Relations Thomas Frings, Celesio AG, +49 (0)711.5001-532 investor@celesio.com Media Dr. Jens Schreiber, Celesio AG, +49 (0)711.5001-380 media@celesio.com --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: - Combines capabilities of two of the world's leading pharmacy-driven healthcare companies - Joint Venture focuses on advancing the efficiency of pharmacy through integrated solutions to improve care for patients with chronic and complex health conditions - Supports payors, patients, pharmacists and physicians - Joint-Venture will reduce overall healthcare costs while delivering significant improvements in healthcare quality - Important strategic step for both Celesio and Medco to speed entry into new markets and market segments with high-growth potential 21.06.2010 08:33 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|] --------------------------------------------------------------------------- Language: English Company: Celesio AG Neckartalstr. 155 70376 Stuttgart Deutschland Phone: +49 (0)711 5001-735 Fax: +49 (0)711 5001-736 E-mail: investor@celesio.com Internet: www.celesio.com ISIN: DE000CLS1001 WKN: CLS100 Indices: MDAX Listed: Regulierter Markt in Berlin, Frankfurt (Prime Standard), München, Düsseldorf, Stuttgart; Freiverkehr in Hannover, Hamburg; Terminbörse EUREX End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Celesio AG: Celesio and Medco Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs
| Source: EQS Group AG